Clinical Trial Update: Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and tolerability of vabicaserin in patients with sudden worsening of schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Vabicaserin (vabicaserin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 2 | Status: WITHDRAWN